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Background. Bisphenol A (BPA) is a common chemical used in the manufacture of polycarbonate plastics and epoxy resins, with
>93% of US adults having detectable BPA levels in urine. Recent animal studies have suggested that BPA exposure may have
a role in several mechanisms involved in the development of hypertension, including weight gain, insulin resistance, thyroid
dysfunction, endothelial dysfunction, and oxidative stress. However, no previous human study has examined the association
between markers of BPA exposure and hypertension. Methods. We examined urinary BPA levels in 1380 subjects from the National
Health and Nutritional Examination Survey 2003-2004. Main outcome-of-interest was hypertension, defined as blood pressure-
reducing medication use and/or blood pressures >140/90 mm of Hg (n = 580). Results. We observed a positive association between
increasing levels of urinary BPA and hypertension independent of confounding factors such as age, gender, race/ethnicity, smoking,
body mass index (BMI), diabetes mellitus and total serum cholesterol levels. Compared to tertile 1 (referent), the multivariate-
adjusted odds ratio (95% confidence interval) of hypertension associated with tertile 3 was 1.50 (1.12−2.00); P-trend = 0.007.
The association was consistently present in subgroup analyses by race/ethnicity, smoking status, BMI, and diabetes mellitus.
Conclusions. Urinary BPA levels are associated with hypertension, independent of traditional risk factors.
1. Introduction
Bisphenol A (BPA) is a chemical produced in very high vol-
ume worldwide [1]. It is used extensively in the manufacture
of epoxy resins, polycarbonate plastics, and food and bev-
erage containers and also in cigarette filters and carbonless
copy paper used in credit card receipts and thermal imaging
papers in modern cash registers [1]. Consequently BPA is
one of the commonly exposed environmental chemicals in
humans [2]. Detectable levels of BPA in urine have been
shown to be present in nearly all sampled adults in recent
national surveys conducted in the USA [2, 3].
BPA is considered to be an endocrine-disrupting chemi-
cal and has been shown to have thyroid hormone disrupting
effects [1, 4]. Recent evidence, especially from experimental
animal studies, suggests that BPA exposure may be related
to insulin resistance and may have a role in weight gain and
obesity [5, 6]. Furthermore, recent epidemiological studies
have shown that higher urinary BPA levels are related to
diabetes mellitus [7] as well as to self-reported cardiovascular
disease [8, 9]. Recent studies have also shown that BPA
exposure is related to hyperlipidemia [10], as well as to
increased levels of serum markers of oxidative stress [11],
inflammation [11].
Hypertension is a major public health problem, and it is
also known to be a strong, independent risk factor for CVD
[12]. Several of the biological mechanisms that are known to
be associated with increased risk of hypertension, including
thyroid dysfunction [13], weight gain [14], insulin resistance
[15], hyperlipidemia [16], oxidative stress [17], and higher
systemic inflammation [18], are also related to increased
risk of developing hypertension. However, no previous study
to our knowledge has examined the association between
BPA levels and hypertension in humans. Therefore, we
examined the independent association between urinary
BPA levels and hypertension in the 2003-2004 National
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Health and Nutritional Examination Survey (NHANES), a
contemporary, multiethnic sample of US adults.
2. Methods
The current study is based on data from the NHANES
2003-2004. Detailed description of NHANES study design
and methods are available elsewhere [19]. In brief, the
NHANES survey included a stratified multistage probability
sample representative of the civilian noninstitutionalized
US population. Selection was based on counties, blocks,
households, and individuals within households and included
the oversampling of non-Hispanic blacks and Mexican
Americans in order to provide stable estimates of these
groups. Subjects were required to sign a consent form before
their participation, and approval was obtained from the
Human Subjects Committee in the US Department of Health
and Human Service.
The current study sample consisted of participants aged
greater than 20 years among whom urinary BPA was available
(N = 1, 488). We further excluded participants with missing
data (n = 108) on covariates included in the multivariable
model, including level of education, smoking status, serum
or fasting glucose levels, body mass index (BMI), and
cholesterol levels. This resulted in 1380 participants (49.6%
women), 580 of whom had hypertension.
2.1. Exposure Measurements. Age, gender, race/ethnicity,
smoking status, alcohol intake (g/day), level of education,
history of diabetes and oral hypoglycemic intake or insulin
administration were assessed using a questionnaire [19].
Individuals who had not smoked >100 cigarettes in their
lifetimes were considered never smokers; those who had
smoked >100 cigarettes in their lifetimes were consid-
ered former smokers if they answered negatively to the
question “Do you smoke now?” and current smokers if
they answered affirmatively. Body mass index (BMI) was
calculated as weight in kilograms divided by height in meters
squared.
Rigorous procedures with quality control checks were
used in blood collection, and details about these procedures
are provided in the NHANES Laboratory/Medical Technolo-
gists Procedures Manual [19]. Serum glucose was measured
using the modified hexokinase method at the University of
Missouri Diabetes Diagnostic Laboratory. Diabetes mellitus
was defined based on the recent guidelines of the American
Diabetes Association [20] as a serum glucose >126 mg/dL
after fasting for a minimum of 8 hours, a serum glucose
>200 mg/dL for those who fasted <8 hours before their
NHANES visit, a glycosylated hemoglobin value >6.5%, or
a self-reported current use of oral hypoglycemic medication
or insulin.
Previous measures of BPA in biological matrixes involved
techniques such as gas chromatography (GC) or high-
performance liquid chromatography [21]. To achieve
enhanced sensitivity and selectivity over previous methods,
in the current NHANES, measures of environmental phenols
were derivatized to alkyl or acyl derivatives before GC/mass
spectrometry (GC/MS) analysis [22]. Using solid phase
extraction coupled to high-performance liquid chromatog-
raphy and tandem mass spectrometry, detection levels of
0.1–2 nanograms per milliliter (ng/mL) in 100 μL of urine
were achieved, sufficient for measuring urinary BPA levels in
nonoccupationally exposed participants [22].
2.2. Main Outcome of Interest: Hypertension. Seated sys-
tolic and diastolic blood pressures were measured using a
mercury sphygmomanometer according to the American
Heart Association and the Seventh Joint National Committee
(JNC7) recommendations [12]. Up to 3 measurements were
averaged for systolic and diastolic pressures. Patients were
considered hypertensive if they reported current blood-
pressure-reducing medication use and/or had systolic blood
pressures >140 mm of Hg and/or diastolic blood pressures
>90 mm of Hg [19].
2.3. Statistical Analysis. Urinary BPA was categorized into
tertiles (<1.5 ng/mL, 1.5–4.0 ng/mL, >4.0 ng/mL). We hy-
pothesized that high BPA levels are associated with hyper-
tension. The odds ratio ((OR) (95% confidence interval
(CI)) of hypertension associated with higher BPA levels
was calculated using multivariable logistic regression models
by taking the lowest tertile as the referent. We used two
models: the age, sex-adjusted model and the multivari-
able model, additionally adjusting for race/ethnicity (non-
Hispanic whites, non-Hispanic blacks, Mexican Americans,
others), education categories (below high school, high
school, above high school), smoking (never smoker, for-
mer smoker, current smoker), alcohol intake (nondrinker,
moderate drinker, heavy drinker), BMI (normal, overweight,
obese), hypertension (present, absent), diabetes (present,
absent), and total serum cholesterol (mg/dL). Trends in the
OR of hypertension across increasing urinary BPA categories
were determined by modeling BPA as an ordinal variable.
Sample weights that account for the unequal probabilities of
selection, oversampling, and nonresponse were applied for
all analyses using SAS (version 9.2; SAS Institute, Cary, NC)
and SUDAAN software; SEs were estimated using the Taylor
series linearization method.
3. Results
Table 1 shows the baseline characteristics of the population.
Overall, this was a middle-aged multiethnic sample with
approximately 32% subjects obese, 10% subjects having
diabetes mellitus, and 36.3%% having hypertension.
Table 2 shows the association between increasing levels
of BPA and hypertension. Overall, we observed a positive
association between increasing BPA levels and hypertension
in both the age, sex-adjusted model and the multivariable-
adjusted model. Models evaluating trend in this association
were also statistically significant.
Table 3 shows the association between increasing BPA
levels and hypertension within subgroups of race/ethnicity,
BMI, and diabetes status. We found that the positive
magnitude of association between increasing BPA levels
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Table 1: Baseline characteristics of the study population∗.
Characteristics Whole cohort (n = 1380)
Age (years) 46.2 + 0.5
Female (%) 700 (49.6)
Race/Ethnicity (%)
Non-Hispanic Whites 748 (72.3)
Non-Hispanic Blacks 244 (9.8)
Mexican Americans and others 388 (17.8)
Education categories (%)
Below high school 395 (17.9)
High school 331 (25.3)
Above high school 654 (56.8)
Smoking (%)
Never smoker 691 (50.6)
Former smoker 373 (25.5)
Current smoker 316 (23.9)
Alcohol intake (%)
Non-drinker 544 (34.1)
Moderate drinker 528 (41.7)
Heavy drinker 308 (24.0)
Body mass index (BMI) (%)
Normal weight (<25 kg/m2) 448 (35.0)
Overweight (25–30 kg/m2) 475 (32.9)
Obese (BMI ≥ 30 kg/m2) 457 (32.1)
Diabetes (%) 175 (10.0)
Total cholesterol (mg/dL) 203.81± 1.17
Hypertension (%) 580 (36.3)
∗
Data presented are number (percentages) or mean values ± standard error
(SE), as appropriate for the variable.
and hypertension was consistently present within all these
various stratified subgroups with the multivariable OR
ranging from 1.4 to 1.9. Also, there was no statistically
significant interaction between BPA levels and these variables
(p-interaction >0.10 in all stratified analyses).
We also performed several supplementary analyses. First,
we examined the association between urinary BPA and
hypertension using urinary BPA as a continuous variable
(with natural logarithmic transformation). Consistent with
the categorical BPA analysis, there was a significant positive
association between urinary BPA as a continuous variable
and hypertension with an odds ratio (95% CI) of 1.18
(1.07–1.31); P value = 0.001 in the age-sex-adjusted model
and 1.11 (1.01–1.22); P-value = 0.04 in the multivariable
model for every 1 unit increase in the log-transformed
urinary BPA level. Second, to examine the nonlinearity of
the association between urinary BPA and hypertension, we
added a quadratic term for BPA in the multivariable logistic
regression models. We found that the quadratic term was
not statistically significant (P-value = 0.459 in the age-,
sex-adjusted model and 0.784 in the multivariable-adjusted
model).
4. Discussion
In a large multiethnic, representative sample of US adults,
we found that increasing urinary BPA levels were associated
with hypertension. The observed association was found to
be independent of confounding factors such as smoking,
BMI, alcohol intake, diabetes mellitus, and serum cholesterol
level. Our study adds to the emerging evidence of the role
of environmental exposure to BPA on health outcomes in
humans [8, 9] by being the first study reporting an association
between BPA exposure and hypertension, which is a major
public health condition and a strong risk factor for CVD
[12].
BPA is an environmental chemical used as a constituent
monomer in polycarbonate plastics, which are used exten-
sively in drinks containers and food packaging, and in
the production of oxidants used in the lining of canned
goods [1]. Exposure to BPA is believed to be mainly
through dietary intake with additional exposure through
water, dental sealants, inhalation of household dusts, and
exposure through skin [1]. Recent studies have documented
that over 93 to 95% of the general population has measurable
concentrations of BPA metabolites in urine [2, 3].
Several lines of recent evidence suggest that an asso-
ciation between urinary BPA levels and hypertension may
be biologically plausible. Animal studies have suggested
that BPA exposure may have a role in the development of
hypertension thorough several mechanisms, including BPA’s
role in weight gain and obesity development potentially
through its actions on preadipocytes [23, 24], role as an
estrogen [5], potential interactions with estrogen-related
receptor gamma [25], actions as a thyroid hormone antago-
nist [4], role as a peroxisome proliferator-activated receptor
gamma antagonist [26], and its role in influencing pancreatic
endocrine function [27]. Alonso-Magdalena et al. [28] in
a recent experiment showed that mice exposed to long-
term exposure to BPA developed hyperinsulinemia, insulin
resistance, and glucose intolerance. Furthermore, BPA has
been shown to induce endothelial cell injury mediated
through oxidative stress [29–31] and elevations in lipids [32]
in animal models. In epidemiological studies in humans,
BPA levels were found to be associated with abnormal liver
function enzymes, higher levels of fasting glucose, insulin,
and HOMA-IR insulin resistance [8, 9], all are factors known
to be associated with hypertension development [15, 33].
However, there are no previous studies in humans for
comparison. It is in this context that our results regarding
objectively measured systolic and diastolic blood pressures
to define hypertension in a large sample of US adults are
important. In the current study, we have demonstrated a con-
sistent, positive association between higher BPA levels and
hypertension that was independent of major confounders
and also consistent in stratified analyses by race/ethnicity,
BMI, and diabetes mellitus.
The main strengths of our study include its nationally
representative sample, use of rigorous study methods to
collect the data, and the availability of extensive data on
confounders [19, 22]. The main study limitation is that
the current study is cross-sectional in nature, making it
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Table 2: Association between urinary bisphenol A and hypertension.
Bisphenol A tertiles (ng/mL) Sample size (cases) Age-, sex-adjusted OR (95% CI)∗ Multivariable-adjusted OR (95% CI)∗†
Tertile 1 (<1.5) 447 (180) 1 (referent) 1 (referent)
Tertile 2 (1.5–4.0) 473 (198) 1.27 (0.81–1.98) 1.11 (0.71–1.74)
Tertile 3 (>4.0) 460 (202) 1.74 (1.27–2.38) 1.50 (1.12–2.00)
P trend 0.0006 0.007
∗
OR (95% CI): Odds Ratio (95% Confidence Interval)
†Adjusted for age (years), gender (male, female), race-ethnicity (non-Hispanic whites, non-Hispanic blacks, Mexican Americans, others), education categories
(below high school, high school, above high school), smoking (never, former, current), alcohol intake (nondrinker, moderate drinker, heavy drinker), body
mass index (normal, overweight, obese), diabetes (present, absent), and total cholesterol (mg/dL).
Table 3: Association between urinary bisphenol A (BPA) and hypertension, by stratification variables.
Stratification category Sample size (cases)
Multivariable OR (95% CI)∗† comparing
BPA tertile 3 versus Tertile 1
p-interaction
Race/ethnicity
Non-Hispanic whites 748 (316) 1.42 (0.98–2.06)
Non-Hispanic blacks 244 (121) 1.91 (0.44–8.33) 0.507
Mexican Americans and others 388 (143) 1.50 (0.60–3.72)
Smoking status
Non-smokers 691 (265) 1.62 (1.01–2.59)
0.932Smokers 689 (315) 1.39 (0.74–2.62)
BMI categories
Nonobese 923 (334) 1.37 (0.91–2.06)
0.729Obese 457 (246) 1.84 (0.85–3.99)
Diabetes mellitus/Prediabetes
Absent 896 (282) 1.30 (0.87–1.95)
0.494Present 484 (298) 1.91 (1.08–3.37)
∗
OR (95% CI): Odds Ratio (95% Confidence Interval)
†Adjusted for age (years), gender (male, female), race-ethnicity (non-Hispanic whites, non-Hispanic blacks, Mexican Americans, others), education categories
(below high school, high school, above high school), smoking (never, former, current), alcohol intake (non-drinker, moderate drinker, heavy drinker), body
mass index (normal, overweight, obese), diabetes (present, absent) and total cholesterol (mg/dL).
impossible to draw cause-effects in the observed associations.
Future prospective studies are required to confirm or dis-
prove our findings.
In summary, we found that in a nationally representative
sample of US adults, higher BPA levels were positively
associated with hypertension independent of confounding
factors such as age, gender, smoking, BMI, alcohol intake,
diabetes mellitus, and cholesterol levels. If confirmed in
future prospective studies, reducing environmental exposure
to BPA may have a role in the prevention of hypertension.
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